Previous 10 | Next 10 |
ROCKVILLE, Md. , Feb. 20, 2020 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need, ...
ROCKVILLE, Md . , Feb. 13, 2020 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need, intends ...
ROCKVILLE, Md. , Feb. 7, 2020 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need, announced...
ROCKVILLE, Md. , Feb. 4, 2020 /PRNewswire/ -- Synthetic Biologics , Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need, announce...
(The McLaren 650S Spider - Image Source ) This beautiful image from Ally Financial ( ALLY ) web site initially referred to Ally and McLaren announcing their financing relationship, but perhaps it can also symbolize exciting opportunities with ALLY stock. Introduction A month ago...
Synovus Financial (NYSEMKT: SYN ) falls 1.5% in premarket trading after Q4 adjusted EPS of 94 cents trails the consensus estimate of 97 cents. More news on: Synthetic Biologics, Inc., Financial stocks news, Earnings news and commentary, , Stocks on the move, , Read more ...
Thinly traded nano cap Synthetic Biologics ( SYN +8.7% ) is up a 17x surge in volume in reaction to its update on co-lead candidate SYN-004 (ribaxamase). More news on: Synthetic Biologics, Inc., Healthcare stocks news, Stocks on the move, Read more ...
ROCKVILLE, Md. , Jan. 7, 2020 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need, today ...
ROCKVILLE, Md. , Nov. 27, 2019 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need, today anno...
Synthetic Biologics, Inc. (SYN) Q3 2019 Earnings Conference Call November 04, 2019, 16:30 PM ET Company Participants Vincent Perrone - Director, Corporate Communications Steven Shallcross - CEO and CFO Michael Kaleko - SVP of Research and Development Vince Wacher - Head of Prod...
News, Short Squeeze, Breakout and More Instantly...
Synthetic Biologics Inc. Company Name:
SYN Stock Symbol:
NYSE Market:
Synthetic Biologics Inc. Website:
ROCKVILLE, Md., Oct. 12, 2022 (GLOBE NEWSWIRE) -- Theriva Biologics, Inc. (NYSE American: TOVX), (“Theriva” or the “Company”) is the new name of Synthetic Biologics, Inc. (NYSE American: SYN). The new name, logo and branding elements were introduced to better ref...
ROCKVILLE, Md., Sept. 30, 2022 (GLOBE NEWSWIRE) -- Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need, today announced the presentation of new data from collaborators at Fund...
- The DSMC has reviewed the safety and pharmacokinetic data from Cohort 1 and recommended that the study may proceed to enroll patients into Cohort 2 - ROCKVILLE, Md., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical...